ArticleMicrobiology spectrum2026
HERV6196 as an enhancer with oncogenic potential in rectal cancer.
Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Colorectal cancer (CRC) is among the most prevalent malignancies. However, the regulatory networks involved in tumor occurrence and development are still poorly understood. Human endogenous retroviruses (HERVs), a class of transposable elements, have been implicated in the development and progression of various human cancers. This study presents the first comprehensive locus-specific profiling of the expression of HERV gene transcripts in rectal cancer, revealing significantly dysregulated HERVs. Analysis of data from three Gene Expression Omnibus data sets revealed 25 upregulated HERVs and 7 downregulated HERVs. Dysregulation of HERV6196, a type of HERVH, was validated through reverse transcription quantitative PCR and droplet digital PCR in cells and tissues. Additionally, HERV6196 promoted the proliferation, inhibited the apoptosis, enhanced the colony formation ability, and enhanced the migration capability of rectal cancer cells. Moreover, HERV6196 functioned as an enhancer, promoting the expression of neighboring genes and the development of CRC. In summary, the present results revealed that HERV6196 is involved in the pathogenesis of rectal cancer, indicating the potential contribution of dysregulated HERVs to the development and progression of CRC through gene expression modulation.IMPORTANCEThe role of human endogenous retroviruses (HERVs) in colorectal cancer (CRC) remains insufficiently understood. The present study revealed aberrant expression of HERV gene transcripts in cancerous tissues compared with non-cancerous tissues. HERV6196 contributes to CRC progression by regulating the expression of neighboring genes. These findings suggest that HERVs may serve as enhancers and regulate oncogenic gene expression, providing new insights for rewiring transcriptional regulatory networks in CRC pathogenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.